vs
AdvanSix Inc.（ASIX）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是AdvanSix Inc.的1.7倍（$622.0M vs $359.9M），Royalty Pharma plc净利率更高（34.4% vs -0.8%，领先35.2%），AdvanSix Inc.同比增速更快（9.4% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 3.4%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ASIX vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.7倍
$359.9M
营收增速更快
ASIX
高出4.6%
4.8%
净利率更高
RPRX
高出35.2%
-0.8%
两年增速更快
RPRX
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $622.0M |
| 净利润 | $-2.8M | $214.2M |
| 毛利率 | 7.6% | — |
| 营业利润率 | -0.7% | 62.4% |
| 净利率 | -0.8% | 34.4% |
| 营收同比 | 9.4% | 4.8% |
| 净利润同比 | -892.9% | 2.9% |
| 每股收益（稀释后） | $-0.11 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXRPRX
| Q4 25 | $359.9M | $622.0M | ||
| Q3 25 | $374.5M | $609.3M | ||
| Q2 25 | $410.0M | $578.7M | ||
| Q1 25 | $377.8M | $568.2M | ||
| Q4 24 | $329.1M | $593.6M | ||
| Q3 24 | $398.2M | $564.7M | ||
| Q2 24 | $453.5M | $537.3M | ||
| Q1 24 | $336.8M | $568.0M |
净利润ASIXRPRX
| Q4 25 | $-2.8M | $214.2M | ||
| Q3 25 | $-2.6M | $288.2M | ||
| Q2 25 | $31.4M | $30.2M | ||
| Q1 25 | $23.3M | $238.3M | ||
| Q4 24 | $352.0K | $208.2M | ||
| Q3 24 | $22.3M | $544.0M | ||
| Q2 24 | $38.9M | $102.0M | ||
| Q1 24 | $-17.4M | $4.8M |
毛利率ASIXRPRX
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
营业利润率ASIXRPRX
| Q4 25 | -0.7% | 62.4% | ||
| Q3 25 | -0.9% | 70.1% | ||
| Q2 25 | 7.7% | 36.3% | ||
| Q1 25 | 7.7% | 94.0% | ||
| Q4 24 | -3.9% | 60.9% | ||
| Q3 24 | 7.5% | — | ||
| Q2 24 | 11.5% | 50.2% | ||
| Q1 24 | -7.0% | -13.0% |
净利率ASIXRPRX
| Q4 25 | -0.8% | 34.4% | ||
| Q3 25 | -0.7% | 47.3% | ||
| Q2 25 | 7.7% | 5.2% | ||
| Q1 25 | 6.2% | 41.9% | ||
| Q4 24 | 0.1% | 35.1% | ||
| Q3 24 | 5.6% | 96.3% | ||
| Q2 24 | 8.6% | 19.0% | ||
| Q1 24 | -5.2% | 0.8% |
每股收益（稀释后）ASIXRPRX
| Q4 25 | $-0.11 | $0.49 | ||
| Q3 25 | $-0.10 | $0.67 | ||
| Q2 25 | $1.15 | $0.07 | ||
| Q1 25 | $0.86 | $0.55 | ||
| Q4 24 | $0.02 | $0.46 | ||
| Q3 24 | $0.82 | $1.21 | ||
| Q2 24 | $1.43 | $0.23 | ||
| Q1 24 | $-0.65 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $815.2M | $9.7B |
| 总资产 | $1.7B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ASIXRPRX
| Q4 25 | $19.8M | $618.7M | ||
| Q3 25 | $23.7M | $938.9M | ||
| Q2 25 | $18.4M | $631.9M | ||
| Q1 25 | $8.3M | $1.1B | ||
| Q4 24 | $19.6M | $929.0M | ||
| Q3 24 | $17.3M | $950.1M | ||
| Q2 24 | $12.1M | $1.8B | ||
| Q1 24 | $20.6M | $843.0M |
总债务ASIXRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益ASIXRPRX
| Q4 25 | $815.2M | $9.7B | ||
| Q3 25 | $818.2M | $9.6B | ||
| Q2 25 | $823.7M | $9.5B | ||
| Q1 25 | $794.4M | $9.8B | ||
| Q4 24 | $774.6M | $10.3B | ||
| Q3 24 | $766.4M | $10.3B | ||
| Q2 24 | $746.6M | $9.8B | ||
| Q1 24 | $713.2M | $9.9B |
总资产ASIXRPRX
| Q4 25 | $1.7B | $19.6B | ||
| Q3 25 | $1.7B | $19.3B | ||
| Q2 25 | $1.6B | $18.3B | ||
| Q1 25 | $1.6B | $17.6B | ||
| Q4 24 | $1.6B | $18.2B | ||
| Q3 24 | $1.5B | $18.0B | ||
| Q2 24 | $1.5B | $17.7B | ||
| Q1 24 | $1.5B | $16.1B |
负债/权益比ASIXRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | — |
| 自由现金流率自由现金流/营收 | 10.0% | — |
| 资本支出强度资本支出/营收 | 7.7% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $6.4M | — |
8季度趋势，按日历期对齐
经营现金流ASIXRPRX
| Q4 25 | $63.7M | $827.1M | ||
| Q3 25 | $26.6M | $702.6M | ||
| Q2 25 | $21.1M | $364.0M | ||
| Q1 25 | $11.4M | $596.1M | ||
| Q4 24 | $64.2M | $742.5M | ||
| Q3 24 | $57.3M | $703.6M | ||
| Q2 24 | $50.2M | $658.2M | ||
| Q1 24 | $-36.2M | $664.6M |
自由现金流ASIXRPRX
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | — | ||
| Q2 25 | $-7.2M | — | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | — | ||
| Q2 24 | $16.7M | — | ||
| Q1 24 | $-71.6M | — |
自由现金流率ASIXRPRX
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | -1.7% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -21.3% | — |
资本支出强度ASIXRPRX
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 7.4% | — | ||
| Q1 24 | 10.5% | — |
现金转化率ASIXRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 0.67× | 12.06× | ||
| Q1 25 | 0.49× | 2.50× | ||
| Q4 24 | 182.29× | 3.57× | ||
| Q3 24 | 2.57× | 1.29× | ||
| Q2 24 | 1.29× | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
